A phase IV, double-blind, placebo-controlled, randomized withdrawal trial to evaluate the use of sodium zirconium cyclosilicate (CSZ) for the treatment of hyperkalemia in patients with symptomatic heart failure with a D fraction.

CLINICAL TRIAL WITH MEDICINES